# EDGAR Filing Document

**Accession Number:** 0000882095
**File Stem:** 0001123292-23-000027
**Filing Date:** 2023-2
**Character Count:** 12706
**Document Hash:** ffdb46522a0f1593e1871710bab69eaf
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001123292-23-000027.hdr.sgml**: 20230214

**ACCESSION NUMBER**: 0001123292-23-000027

**CONFORMED SUBMISSION TYPE**: SC 13G/A

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20230214

**DATE AS OF CHANGE**: 20230214

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** HOOKIPA Pharma Inc.
- **CENTRAL INDEX KEY:** 0001760542
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 815395687
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-90985
- **FILM NUMBER:** 23626887

**BUSINESS ADDRESS:**
- **STREET 1:** 430 EAST 29TH STREET
- **STREET 2:** 14TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10016
- **BUSINESS PHONE:** 0114318906360

**MAIL ADDRESS:**
- **STREET 1:** 430 EAST 29TH STREET
- **STREET 2:** 14TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10016
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GILEAD SCIENCES, INC.
- **CENTRAL INDEX KEY:** 0000882095
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 943047598
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A

**BUSINESS ADDRESS:**
- **STREET 1:** 333 LAKESIDE DR
- **CITY:** FOSTER CITY
- **STATE:** CA
- **ZIP:** 94404
- **BUSINESS PHONE:** 6505743000

**MAIL ADDRESS:**
- **STREET 1:** 333 LAKESIDE DR
- **CITY:** FOSTER CITY
- **STATE:** CA
- **ZIP:** 94404

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GILEAD SCIENCES INC
- **DATE OF NAME CHANGE:** 19930328

------

### <br>

### SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

------

**SCHEDULE 13G**

#### Under the Securities Exchange Act of 1934

#### (Amendment No. 4)\*

---

| |
|:---|
| **** <br>**HOOKIPA PHARMA INC.**<br>|
| (Name of Issuer) |
| **<br>Common Stock, par value $0.0001 per share**<br>|
| (Title of Class of Securities) |
| <br>**43906K 100**<br>|
| (CUSIP Number) |
| **March 24, 2022** |
| (Date of Event Which Requires Filing of this Statement) |

---

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b) <br> ☒ Rule 13d-1(c) <br> ☐ Rule 13d-1(d)

![](image2.jpg)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

![](image3.jpg)

------

---

| | | |
|:---|:---|:---|
| **CUSIP NO.** | **43906K 100** | ****<br>|

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br>

---

| | | |
|:---|:---|:---|
| **1** | **NAMES OF REPORTING PERSONS** | **NAMES OF REPORTING PERSONS** |
| **1** |  |  |
| **1** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Gilead Sciences, Inc.** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Gilead Sciences, Inc.** |
| **1** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Gilead Sciences, Inc.** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Gilead Sciences, Inc.** |
| **2** | **CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)** | **CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)** |
| **2** | (a) ☐ | (a) ☐ |
| **2** | (b) ☐ | (b) ☐ |
| **3** | **SEC USE ONLY** | **SEC USE ONLY** |
| **3** |  |  |
| **3** |  |  |
| **4** | **CITIZENSHIP OR PLACE OF ORGANIZATION** | **CITIZENSHIP OR PLACE OF ORGANIZATION** |
| **4** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **State of Delaware** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **State of Delaware** |
| **4** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **State of Delaware** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **State of Delaware** |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:** | **5** | **SOLE VOTING POWER** |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:** | **5** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **3759465<br> ** |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:** | **5** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **3759465<br> ** |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:** | **6** | **SHARED VOTING POWER** |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:** | **6** | <br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br>**-0-**<br> **** <br>|
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:** | **7** | **SOLE DISPOSITIVE POWER** |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:** | **7** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **3759465<br> ** |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:** | **7** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **3759465<br> ** |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:** | **8** | **SHARED DISPOSITIVE POWER** |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:** | **8** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **-0-** |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:** | **8** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; **-0-** |
| **9** | **AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON** | **AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON** |
| **9** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **3759465<br> ** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **3759465<br> ** |
| **9** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **3759465<br> ** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **3759465<br> ** |
| **10** | **CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐** | **CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐** |
| **10** |  |  |
| **10** |  |  |
| **11** | **PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)** | **PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)** |
| **11** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **7.2%[<sup>1</sup>](#Ft1)** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **7.2%[<sup>1</sup>](#Ft1)** |
| **11** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **7.2%[<sup>1</sup>](#Ft1)** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **7.2%[<sup>1</sup>](#Ft1)** |
| **12** | **TYPE OF REPORTING PERSON\*** | **TYPE OF REPORTING PERSON\*** |
| **12** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **CO** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **CO** |
| **12** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **CO** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **CO** |

---

------

1 Based on 52,317,138 shares of the common stock of the Issuer (the "Common Stock") issued and outstanding as of November 7, 2022, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on November 14, 2022.

------

---

| | |
|:---|:---|
| **Item 1(a)** | **<u>Name of Issuer:</u>** |
|  | The name of the issuer is HOOKIPA Pharma Inc. (the "Issuer"). |
| **Item 1(b)** | **<u>Address of Issuer's Principal Executive Offices:</u>** |
|  | The Issuer's principal executive offices are located at 350 Fifth Avenue, 72nd Floor, Suite 7240, New York, NY 10118. |
| **Item 2(a)** | **<u>Name of Person Filing:</u>** |
|  | This Amendment No. 4 to Schedule 13G is being filed by Gilead Sciences, Inc. (the "Reporting Person"). |
| **Item 2(b)** | **<u>Address of Principal Business Office or, if none, Residence:</u>** |
|  | The address of the principal business office of the Reporting Person is 333 Lakeside Drive, Foster City, California, 94404. |
| **Item 2(c)**<br> **** <br>| **<u>Citizenship:</u>** |
|  | The Reporting Person is incorporated in the State of Delaware.<br>|
| **Item 2(d)** | **<u>Title of Class of Securities:</u>** |
|  | Common Stock, par value $0.0001 per share |
| **Item 2(e)** | **<u>CUSIP No.:</u>** |
|  | <br>43906K 100<br>|
| **Item 3** | **<u>If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b), check whether the person filing is a:</u>** |
|  | Not applicable. |

---

------

---

| | |
|:---|:---|
| **Item 4**<br>| **<u>Ownership:</u>** |

---

---

| | | |
|:---|:---|:---|
| (a) | &nbsp;&nbsp;&nbsp;&nbsp;Amount beneficially owned: 3,759,465  | &nbsp;&nbsp;&nbsp;&nbsp;Amount beneficially owned: 3,759,465  |
| (b) | &nbsp;&nbsp;&nbsp;&nbsp;Percent of class: 7.2%[<sup>2</sup>](#Ft2) | &nbsp;&nbsp;&nbsp;&nbsp;Percent of class: 7.2%[<sup>2</sup>](#Ft2) |
| (c) | &nbsp;&nbsp;&nbsp;&nbsp;Number of shares as to which such person has:  | &nbsp;&nbsp;&nbsp;&nbsp;Number of shares as to which such person has:  |
|  | (i) | &nbsp;&nbsp;&nbsp;&nbsp;Sole power to vote or direct the vote: 3,759,465 |
|  | (ii) | &nbsp;&nbsp;&nbsp;&nbsp;Shared power to vote or direct the vote: -0- |
|  | (iii) | &nbsp;&nbsp;&nbsp;&nbsp;Sole power to dispose or direct the disposition: 3,759,465 |
|  | (iv) | &nbsp;&nbsp;&nbsp;&nbsp;Shared power to dispose or direct the disposition: -0- |

---

2 Based on 52,317,138 shares of the Common Stock issued and outstanding as of November 7, 2022, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2022.

------

---

| | |
|:---|:---|
| **Item 5** | **<u>Ownership of Five Percent or Less of a Class:</u>** |
|  | <br>If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐. |
| **Item 6** | **<u>Ownership of More Than Five Percent on Behalf of Another Person:</u>** |
|  | Not applicable. |
| **Item 7** | **<u>Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:</u>** |
|  | Not applicable. |
| **Item 8** | **<u>Identification and Classification of Members of the Group:</u>** |
|  | Not applicable. |
| **Item 9** | **<u>Notice of Dissolution of Group:</u>** |
|  | Not applicable. |
| **Item 10** | **<u>Certification:</u>** |
|  | By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. |

---

------

**** 

<br> **SIGNATURE**

**** 

<br> After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Amendment No. 4 to Schedule 13G is true, complete and correct.

Dated: February 14, 2023

---

| | |
|:---|:---|
| **GILEAD SCIENCES, INC.** | **GILEAD SCIENCES, INC.** |
| By: | /s/ Andrew D. Dickinson |
| Name: | Andrew D. Dickinson |
| Title: | Executive Vice President and Chief Financial Officer |

---

<br>